Hyloris Pharmaceuticals SA (EBR:HYL)
Belgium
· Delayed Price · Currency is EUR 5.28
-0.06 (-1.12%)
Apr 29, 2026, 2:38 PM CET
Hyloris Pharmaceuticals Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 13.78 | 23.59 | 30.41 | 33.46 | 50.01 | Upgrade
|
| Short-Term Investments | 0.49 | 0.56 | 0.5 | 10.47 | 0.53 | Upgrade
|
| Cash & Short-Term Investments | 14.27 | 24.15 | 30.91 | 43.93 | 50.54 | Upgrade
|
| Cash Growth | -40.92% | -21.86% | -29.64% | -13.09% | -21.53% | Upgrade
|
| Accounts Receivable | 5.15 | 4.86 | 3.57 | 4.13 | 2.32 | Upgrade
|
| Other Receivables | 0.36 | 0.51 | 0.24 | - | - | Upgrade
|
| Receivables | 5.52 | 5.37 | 3.81 | 4.13 | 2.32 | Upgrade
|
| Inventory | 0.05 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 0.13 | 0.19 | 0.59 | 1.75 | 1.1 | Upgrade
|
| Other Current Assets | -0 | - | - | - | - | Upgrade
|
| Total Current Assets | 19.96 | 29.71 | 35.31 | 49.8 | 53.96 | Upgrade
|
| Property, Plant & Equipment | 1.69 | 1.99 | 2.15 | 1.06 | 0.3 | Upgrade
|
| Long-Term Investments | 3.54 | 3.75 | 4.8 | 4.95 | 4.53 | Upgrade
|
| Other Intangible Assets | 5.69 | 1.76 | 3.83 | 1.81 | 1.85 | Upgrade
|
| Long-Term Accounts Receivable | 2.48 | 2.05 | 1.59 | 1.31 | 1.71 | Upgrade
|
| Long-Term Deferred Charges | - | 2.08 | - | 1.68 | 1.09 | Upgrade
|
| Other Long-Term Assets | 0 | - | - | 0.12 | - | Upgrade
|
| Total Assets | 33.36 | 41.34 | 47.68 | 60.73 | 63.44 | Upgrade
|
| Accounts Payable | 4.7 | 3.17 | 3.2 | 2.3 | 2.62 | Upgrade
|
| Accrued Expenses | - | 0.26 | 0.12 | 0.07 | 0.08 | Upgrade
|
| Current Portion of Long-Term Debt | - | 0.05 | - | - | 8.62 | Upgrade
|
| Current Portion of Leases | 0.36 | 0.28 | 0.24 | 0.14 | 0.07 | Upgrade
|
| Current Income Taxes Payable | - | - | - | - | 0.35 | Upgrade
|
| Current Unearned Revenue | - | - | 0.01 | - | - | Upgrade
|
| Other Current Liabilities | 0.08 | 3.41 | 3.2 | 3.26 | 3.25 | Upgrade
|
| Total Current Liabilities | 5.13 | 7.16 | 6.76 | 5.77 | 14.98 | Upgrade
|
| Long-Term Debt | - | 0.05 | - | - | - | Upgrade
|
| Long-Term Leases | 1.25 | 1.44 | 1.51 | 0.75 | 0.11 | Upgrade
|
| Other Long-Term Liabilities | 0.5 | 0.54 | 0.34 | 0.3 | 0.3 | Upgrade
|
| Total Liabilities | 6.88 | 9.19 | 8.61 | 6.82 | 15.39 | Upgrade
|
| Common Stock | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 | Upgrade
|
| Additional Paid-In Capital | 121.51 | 121.51 | 121.51 | 121.51 | 103.69 | Upgrade
|
| Retained Earnings | -92.8 | -86.47 | -80.76 | -65.38 | -54.81 | Upgrade
|
| Comprehensive Income & Other | -2.37 | -3.04 | -1.82 | -2.36 | -0.96 | Upgrade
|
| Total Common Equity | 26.48 | 32.14 | 39.07 | 53.91 | 48.06 | Upgrade
|
| Shareholders' Equity | 26.48 | 32.14 | 39.07 | 53.91 | 48.06 | Upgrade
|
| Total Liabilities & Equity | 33.36 | 41.34 | 47.68 | 60.73 | 63.44 | Upgrade
|
| Total Debt | 1.61 | 1.82 | 1.75 | 0.89 | 8.79 | Upgrade
|
| Net Cash (Debt) | 12.66 | 22.34 | 29.15 | 43.04 | 41.75 | Upgrade
|
| Net Cash Growth | -43.33% | -23.39% | -32.27% | 3.09% | -25.39% | Upgrade
|
| Net Cash Per Share | 0.46 | 0.80 | 1.04 | 1.58 | 1.62 | Upgrade
|
| Filing Date Shares Outstanding | 27.73 | 28 | 28 | 28 | 25.83 | Upgrade
|
| Total Common Shares Outstanding | 27.73 | 28 | 28 | 28 | 25.83 | Upgrade
|
| Working Capital | 14.83 | 22.55 | 28.55 | 44.03 | 38.98 | Upgrade
|
| Book Value Per Share | 0.95 | 1.15 | 1.40 | 1.93 | 1.86 | Upgrade
|
| Tangible Book Value | 20.79 | 30.39 | 35.24 | 52.1 | 46.2 | Upgrade
|
| Tangible Book Value Per Share | 0.75 | 1.09 | 1.26 | 1.86 | 1.79 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.